Biotech Values

[DewDiligence]

AGN—The evaluations in the phase-2 DARPin study were made at 8-32 weeks, depending on the endpoint. If the main DARPin problem were insufficient duration of a strongly positive response, AGN might have said so rather than just noting that there was insufficient differentiation from Lucentis. On the other hand, AGN typically plays its cards very close to the vest, so maybe the problem really is duration and they’re just not saying so.

p.s. Correction: The clinicaltrials.gov link for the phase-2 DARPin study is http://www.clinicaltrials.gov/ct2/show/NCT01397409 (not the link I posted earlier in this thread).

p.p.s. AGN said the setback to AGN-150998 will have no effect on the timeline for the dual (VEGF/PDGF) DARPin that is in preclinical development. It remains slated for an IND filing in late 2014.